Olema Oncology

Olema Oncology is a biopharmaceutical company based in San Francisco, California. The company employs 88 people and generates approximately $50 million in annual revenue. Olema Oncology focuses on developing targeted therapies specifically for women's cancers. Their primary program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) designed to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Currently, Olema Oncology is conducting a Phase 1/2 dose-escalation and expansion clinical trial for OP-1250. The company benefits from the expertise of experienced scientists, accomplished board members, leading healthcare investors, and innovative pharmaceutical companies. For more information about Olema Oncology, please visit their website at www.olema.com.